Bolag
New Nordic Healthbrands är verksamt inom utveckling och marknadsföring av kosttillskott och naturläkemedel. Största delen av sortimentet utgörs av hälsofrämjande örter. Produkterna säljs via bolagets återförsäljare och tillskotten används exempelvis inom hud- och hårvård, för förbättring av immunsystemet och synförmågan, samt som generella vitamintillskott. Huvudkontoret ligger i Malmö.
Karl Kristian Bergman Jensen, Verkställande direktör (VD), har rapporterat en avyttring om 10 000 aktier till 16,84 SEK per aktie. Källa: Finansinspektionens insynsregister.
Karl Kristian Bergman Jensen, Verkställande direktör (VD), har rapporterat en avyttring om 10 000 aktier till 16,97 SEK per aktie. Källa: Finansinspektionens insynsregister.
Karl Kristian Bergman Jensen, Verkställande direktör (VD), har rapporterat en avyttring om 10 000 aktier till 17,08 SEK per aktie. Källa: Finansinspektionens insynsregister.
Karl Kristian Bergman Jensen, Verkställande direktör (VD), har rapporterat en avyttring om 10 000 aktier till 17,9 SEK per aktie. Källa: Finansinspektionens insynsregister.
The second quarter (April 1, 2026 - June 30, 2026) • The Group's net sales increased by 14.5% during the quarter to SEK 163.8 million (SEK 143.0 million). In local currencies, the increase was 16.3%. • The gross margin decreased to 63.5% (64.8%), while gross profit increased to SEK 104.1 million (SEK 92.6 million). • Operating profit (EBIT) improved to SEK 9.0 million (SEK 3.8 million). • Net profit for the period improved to SEK 7.3 million (SEK 2.1 million), corresponding to SEK 1.18 (SEK 0.34) per share*. • Cash flow from operating activities amounted to SEK 5.3 million (SEK 3.5 million). The first half of the year (January 1, 2026 - June 30, 2026) • Group's net sales increased by 3.3% during the first six months of the year to SEK 296.2 million (SEK 286.8 million). In local currencies, the increase was 7.7%. • The gross margin decreased to 63.0% (64.7%), while gross profit amounted to SEK 186.7 million (SEK 185.5 million). • Operating profit (EBIT) amounted to SEK 7.5 million (SEK 8.7 million). • Net profit for the period decreased to SEK 4.4 million (SEK 4.8 million), corresponding to SEK 0.72 (SEK 0.77) per share*. • Cash flow from operating activities amounted to negative SEK 5.7 million (negative SEK 2.8 million). * There are no dilution effects
Aktieägarna i New Nordic Healthbrands AB (publ) kallas härmed till årsstämma. Plats: Quality Hotel ViewAdress: Hyllie Stationstorg 29, 215 32 MalmöTid: Onsdagen den 29 april 2026 kl. 10.00
The fourth quarter (1 October 2025 - 31 December 2025) • The Group's net revenue in SEK increased by 0.6 percent during the quarter to SEK 150.6 million (SEK 149.6 million). In local currencies, the increase was 8 percent. • The gross margin was in line with the previous year at 62.7 percent (62.8 percent), while gross profit amounted to SEK 94.4 million (SEK 93.9 million). • Operating profit improved to SEK 3.7 million (SEK 1.0 million). • Profit for the period after tax improved to SEK 2.0 million (SEK 1.9 million), corresponding to SEK 0.33 (SEK 0.31) per share*. • Cash flow from operating activities amounted to SEK 8.6 million (SEK 11.2 million). Twelve months (1 January 2025 - 31 December 2025) • The Group's net revenue in SEK increased by 4.7 percent for the full year to SEK 576.4 million (SEK 550.3 million). In local currencies, the increase was 9.6 percent. • The gross margin decreased to 64.3 percent (64.5 percent), and gross profit amounted to SEK 370.4 million (SEK 354.7 million). • Operating profit improved to SEK 15.1 million (SEK -4.4 million). • Profit for the period after tax improved to SEK 8.2 million (SEK -7.7 million), corresponding to SEK 1.32 (SEK -1.24) per share*. • Cash flow from operating activities amounted to SEK 8.4 million (SEK -5.4 million). * There are no dilution effects